Histone acetyltransferases: function, structure, and catalysis
R Marmorstein, SY Roth - Curr. Opin. Genet. Dev, 2001 - dnassist.org
... Other acetylated proteins identified to date include transcriptional regulators
(p53, E2F1, EKLF, GATA1, HMGI[Y], TCF, HNF4, TFIIEβ, and TFIIF), structural ...
Cited by 54 - View as HTML - Web Search - ncbi.nlm.nih.gov - Get it from MIT Libraries

Histone deacetylase inhibitors: from target to clinical trials
WK Kelly, OA O'Connor, PA Marks - Expert Opinion on Investigational Drugs, 2002 - dx.doi.org
... 35-37] . HATs also target non-histone proteins, including various
transcription factors, such as p53, E2F1 and GATA1 [35] . The ...
Cited by 42 - Web Search - ashley-pub.com - ingentaconnect.com - ncbi.nlm.nih.gov - all 6 versions » - Get it from MIT Libraries

Role of histone deacetylase inhibitors in the treatment of cancer (Review). - Full text - MIT Libraries
S MEI, AD HO, U MAHLKNECHT - INTERNATIONAL JOURNAL OF ONCOLOGY, 2004 - 147.52.72.117
... of histone proteins in the vicinity of promoters and of non-histone proteins, such
as transcription factors (eg, p53, YY1, PLZF, CoREST, E2F, GATA1, TFIIE and ...
Cited by 4 - View as HTML - Web Search - ncbi.nlm.nih.gov

Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies - Full text - MIT Libraries
KN Bhalla - J Clin Oncol, 2005 - jco.org
... Importantly, HATs and HDACs have also been shown to affect the acetylation status
of lysine residues of transcription factors (eg, p53, E2F1, GATA1, RelA, YY1 ...
Cited by 2 - Web Search - dx.doi.org - jco.org - ncbi.nlm.nih.gov

Histone modification enzymes: novel targets for cancer drugs
R Kristeleit, L Stimson, P Workman, W Aherne - Expert Opinion on Emerging Drugs, 2004 - dx.doi.org
... p300/CBP p300 CBP 300 260 H2A, H2B, H3, H4 H2A, H2B, H3, H4 Co-activators p53,
c-myb, NF-κB, HMG1, HMG14, GATA1, EKLF, ACTR, SRC1, TIF2, AML1, TFIIE, TFIIF ...
Web Search - extenza-eps.com - ashley-pub.com - ingentaconnect.com - all 8 versions »